PlainRecalls
FDA Drug Low Class III Terminated

buPROPion Hydrochloride Extended-Release Tablets, USP (XL), 300mg, 500-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories, NDC 68001-264-03

Reported: September 21, 2016 Initiated: August 4, 2016 #D-1501-2016

Product Description

buPROPion Hydrochloride Extended-Release Tablets, USP (XL), 300mg, 500-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories, NDC 68001-264-03

Reason for Recall

Failed dissolution specifications - the out of specification result for dissolution was identified during 3 month stability testing.

Details

Units Affected
2626 bottles
Distribution
Nationwide and Puerto Rico
Location
Columbus, OH

Frequently Asked Questions

What product was recalled?
buPROPion Hydrochloride Extended-Release Tablets, USP (XL), 300mg, 500-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories, NDC 68001-264-03. Recalled by Amerisource Health Services. Units affected: 2626 bottles.
Why was this product recalled?
Failed dissolution specifications - the out of specification result for dissolution was identified during 3 month stability testing.
Which agency issued this recall?
This recall was issued by the FDA Drug on September 21, 2016. Severity: Low. Recall number: D-1501-2016.